+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025

  • ID: 5137115
  • Report
  • August 2020
  • Region: Saudi Arabia
  • 250 Pages
  • Kuick Research

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Eli - Lilly
  • Merck
  • Oman Pharmaceuticals
  • Roche

"Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025" Report Highlights:


  • Diabetes Drug Market Opportunity: > US$ 1.5 Billion by 2025
  • Diabetes Device Market Opportunity: > US$ 1 Billion by 2025
  • Glucose Monitoring Device Market Absolute Growth: 33% (2019-2025)
  • Oral Hypoglycemic Drugs Market - Availability, Dosage & Price Analysis
  • Insulin Availability, Dosage & Price Analysis
  • Insulin  Delivery Device Market - Availability, Price & Sales Analysis
  • Glucose Monitoring Device Market - Availability & Price Analysis
  • Investments & Collaborations by Leading Market Players

Over the past few years, Saudi Arabia has witnessed exponential economic growth and fortune, which is followed by the swift technological transformation that resulted in major undesirable effects on lifestyle. Consequently, the prevalence of physical inactivity, obesity and sedentary behaviors along with the consumption of high caloric diet, and sugar-sweetened beverages went on the increase and became very common among Saudi society.

The diabetes incidences are increasing rapidly among the kingdom population and the same is expected to remain consistent in upcoming year due to presence of high percentage of obese and overweight population. Unhealthy lifestyle and lack of physical activities are two major factors responsible for the development of diabetes at early age in Saudi Arabian children and it is further observed that the prevalence rate of juvenile diabetes has been increasing continuously during the past few years. Driven by above mentioned factors, the diabetic burden in Saudi Arabia is expected to increase with higher momentum in future, which will ultimately lead to exponential demand of antidiabetic drugs there by driving the overall diabetes drug and insulin delivery market in coming years.

Several different initiatives and programs are undertaken by the regulatory bodies for supporting the diabetic patients in Saudi Arabia. Increasing diabetes patients, drug development in the field of diabetes, presence of generic drugs, government support, technological advancement, rising geriatric population, rising awareness and increasing healthcare and expenditure are the factors that are driving the diabetes market. The pipeline that the country’s research and development center is holding is expected to double the market size at tremendous rate in the near future. Already the market is flooded with several branded and generic diabetes drugs and soon it will be joined by another large numbers of promising diabetes drugs.  Various stake holders of the Saudi Arabia diabetes market are constantly working on the best possible treatment therapies for the diabetic population. To accompany this, the government has also started some healthcare missions that aims at providing the best healthcare solution to the patients who are in the urgent need of a treatment or who have failed earlier treatments. This whole covers a larger portion of the diabetes mellitus patients as a big part of the mission covers arrival of generic drug makers in the country and focusing towards the disease that are observed in larger percentage.

The diabetic population has widely accepted the presence of branded and imported drugs in the country driven by the socio economic parameters, which are apparently leading to accelerating growth of the branded diabetes drugs market in the country. In addition to the presence of branded drugs, the market is also observing an increase in the number of home grown pharmaceutical companies and distributors engaged in research, development and distribution of diabetes drugs in the market.

As per the report findings, it is estimated that soon the market will flourish in all the parameters that are important for a market to dominate the entire diabetes market. Strong brand loyalty and increasing lifestyle diseases are some of the factors that are expected to drive the diabetes drug market in the upcoming timeframe. Furthermore, the country is experiencing growing healthcare infrastructure, increasing per capita income and a large influx of health insurance companies which are estimated to fuel the growing diabetes market.  Such huge penetration of the parameters responsible for market growth is estimated to develop a strong and competitive landscape for the future diabetes market.


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Eli - Lilly
  • Merck
  • Oman Pharmaceuticals
  • Roche

1. Introduction to Saudi Arabia Diabetes Market
1.1 Overview
1.2 Current Market Scenario
2. Saudi Arabia - Diabetes Prevalence & Statistics
2.1 By Population
2.2 By Diabetes Type
2.2.1 Type 1 Diabetes
2.2.2 Type 2 Diabetes
2.3 By Age & Gender
2.4 Obesity & Overweight
3. Saudi Arabia - Pharmaceutical Pricing & Reimbursement Policies
3.1 Pricing Policies
3.1.1 In-Patent Pharmaceuticals
3.1.2 Off-Patent, Generics & Other Locally Manufactured Product
3.2 Procurement & Reimbursement Policies
4. Saudi Arabia - Regulatory Aspects of Pharmaceutical Products
4.1 Gulf Central Committee for Drug Registrations (GCC-DR)
4.2 Regulatory Review Process
4.3 Centralized Registration
4.4 Decentralized Drug Registration Regulation
5. Saudi Arabia - Diabetes Drug Market
5.1 Market Analysis
5.2 Prescription Pattern
6. Saudi Arabia - Oral Hypoglycemic Drugs Market - Availability, Dosage & Price Analysis
6.1 Biguanides (Metformin Hydrochloride)
6.1.1 Glucophage
6.1.2 Glucare XR
6.1.3 Dimetor
6.1.4 Formit XR
6.2 Sulfonylurea
6.2.1 Gliclazide
6.2.2 Glimepiride
6.2.3 Glibenclamide
6.3 DPP-4 Inhibitors
6.3.1 Vildagliptin
6.3.2 Saxagliptin (Onglyza)
6.3.3 Sitagliptin (Januvia)
6.4 SGLT2 Inhibitors
6.4.1 Canagliflozin (Invokana)
6.4.2 Dapagliflozin (Forxiga)
6.4.3 Empagliflozin (Jardiance)
6.5 Others
6.5.1 Meglitinides
6.5.2 Thiazolidinediones
6.5.3 a-Glucosidase Inhibitors
6.6 Combinational Drugs
6.6.1 Metformin & Sulfonylurea Combination
6.6.2 Metformin & DPP-4 Inhibitors Combination
6.6.3 Metformin & SGLT-2 Inhibitors Combination
7. Saudi Arabia Insulin Market - Availability, Dosage & Price Analysis
7.1 Lantus
7.2 Humulin
7.2.1 Humulin 70/30 100U/ml
7.2.2 Humulin N-NPH
7.3 Humalog
7.4 Mixtard
7.5 Apidra
7.6 Insulatard
8. Saudi Arabia - Diabetes Device Market Analysis
9. Saudi Arabia Insulin Delivery Device Market - Availability, Price & Sales Analysis
9.1 Insulin Syringes
9.2 Insulin Pen
9.2.1 Humalog KwikPen
9.2.2 Flexpen
9.2.3 Solostar
9.2.4 NovoPen
9.2.5 Others
9.3 Insulin Pumps
9.4 Insulin Jet Injectors
10. Saudi Arabia - Glucose Monitoring Device Market - Availability & Price Analysis
10.1 Self-Monitoring Blood Glucose Devices
10.2 Continuous Glucose Monitoring Device
11. Saudi Arabia Diabetes Market – Clinical Insight12. Saudi Arabia Diabetes Market - Investments & Collaborations by Leading MNCs
13. Saudi Arabia Diabetes Market Dynamics
13.1 Market Drivers
13.2 Challenges for Saudi Arabia Diabetes Market
14. Saudi Arabia Diabetes Drug Market Future Outlook
15. Competitive Landscape
15.1 Abbott
15.2 Aljazeera Pharmaceutical Industries
15.3 Al Mojil Drug Company
15.4 AstraZeneca
15.5 Bayer
15.6 CAD Middle-East Pharmaceutical Company
15.7 Eli - Lilly
15.8 Julphur Pharmaceuticals
15.9 Kuwait Saudi Pharmaceutical Company
15.10 Merck
15.11 Novartis
15.12 Oman Pharmaceuticals
15.13 Roche
15.14 Saja Pharmaceuticals
15.15 Sanofi
15.16 Servier
15.17 SPIMACO Addwaeih
15.18 Tabuk Pharmaceuticals
15.19 Qatar Life Pharma
15.20 YIACO Medical Company
List of Figures
Figure 1-1: Adult Diabetic Population - MEA v/s Saudi Arabia (Million), 2019
Figure 1-2: Adult Diabetic Population - Saudi Arabia v/s Rest of MEA (%), 2019
Figure 1-3: Adult Diabetic Population - GCC v/s Saudi Arabia (Million), 2019
Figure 1-4: Adult Diabetic Population - Saudi Arabia v/s Rest of GCC (%), 2019
Figure 1-5: Saudi Arabia Healthcare Expenditure - Total v/s Diabetes (US$ Billion), 2018
Figure 1-6: Saudi Arabia Healthcare Expenditure - Diabetes v/s Other Diseases (%), 2018
Figure 1-7: Middle East - Diabetes Drug Market Opportunity (US$ Billion), 2019-2025
Figure 1-8: Middle East v/s Saudi Arabia - Diabetes Drug Market Size (US$ Billion), 2019
Figure 1 9: Saudi Arabia - Diabetes Device Market Size - Total v/s Blood Glucose Monitoring Device (US$ Million), 2019
Figure 2-1: Saudi Arabia - Adult Diabetic Population (Million), 2017 & 2019
Figure 2-2: Saudi Arabia - Estimated Number of Adult Diabetic Population (Million), 2030 & 2045
Figure 2-3: Saudi Arabia Adult Diabetic Population - Diagnosed v/s Undiagnosed (Million), 2019
Figure 2-4: Saudi Arabia - Adult Diabetic Population Share - Diagnosed v/s Undiagnosed (%), 2019
Figure 2-5: Saudi Arabia - Population Estimates (Million), 2019, 2020, 2025 & 2030
Figure 2-6: Saudi Arabia Population by Age (Million), 2019
Figure 2-7: Saudi Arabia - Adult Population (Million), 2019, 2030 & 2045
Figure 2-8: Saudi Arabia - Age Adjusted Diabetes Prevalence Rate (%), 2019, 2025 & 2045
Figure 2-9: Saudi Arabia - Diabetes Related Deaths, 2010 & 2019
Figure 2-10: Saudi Arabia - Adult Diabetes Cases by Type (Million), 2019
Figure 2-11: Saudi Arabia - Diabetes Cases by Type (%), 2019
Figure 2-12:  Saudi Arabia - Type 1 Diabetic Adult Population (Million), 2019, 2025 & 2045
Figure 2-13: Saudi Arabia - Total & Newly Diagnosed Type 1 Diabetic Cases in Age below 19 Years, 2019
Figure 2-14: Saudi Arabia - Type Diabetic Population (Million), 2019, 2025 & 2045
Figure 2-15: Saudi Arabia - Diabetes Prevalence Rate by Gender (%), 2016
Figure 2-16: Saudi Arabia - Diabetic Population by Gender (Million), 2016
Figure 2-17: Saudi Arabia - Diabetes Cases by Age (%), 2017
Figure 2-18: Saudi Arabia - Newly Diagnosed Type 1 Diabetes Cases in Children by Age, 2019
Figure 2-19: Saudi Arabia - Type 1 Diabetes Cases in Children by Age, 2019
Figure 2-20: Saudi Arabia - Type 1 Diabetes Cases in Children by Age (%), 2019
Figure 2-21: Saudi Arabia - Obesity Prevalence Rate (%), 2016 & 2019
Figure 2-22: Saudi Arabia - Obese Population (Million), 2016 & 2019
Figure 2-23: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2016
Figure 2-24: Saudi Arabia - Overweight Prevalence Rate by Gender (%), 2016
Figure 2-25: Saudi Arabia - Physical Inactivity Prevalence Rate by Gender (%), 2016
Figure 4-1: Saudi Arabia - Types of Drug Registration Process
Figure 4-2: Process Map for GCC Centralized Registration
Figure 4-3: GCC – Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US$), 2019
Figure 4-4: GCC – Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US$), 2019
Figure 4-5: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US$), 2019
Figure 4-6: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US$), 2019
Figure 4-7: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US$), 2019
Figure 4-8: Saudi Arabia – Regulatory Process for Pharmaceuticals
Figure 5-1: Saudi Arabia - Diabetes Drug Market Size (US$ Million), 2019 - 2025
Figure 5-2: Saudi Arabia - Patients on Single, Double & Triple Drug Therapy for Diabetes Management (%), 2018
Figure 5-3: Saudi Arabia - Prescription Share of Anti-Diabetic Drugs (%), 2018
Figure 5-4: Saudi Arabia - Sulfonylurea Drug’s Prescription Share by products (%), 2018
Figure 5-5: Saudi Arabia - Insulin Prescription Share by Type (%), 2018
Figure 6-1: Metformin - Recommended Initial, Maintenance & Maximum Dose of Immediate Release Tablet for Adults (mg/day), January’2020
Figure 6-2: Metformin - Recommended Initial & Maximum Dose of Extended Release Tablet for Adults (mg/day), January’2020
Figure 6-3: Metformin - Recommended Initial & Maximum Dose of Immediate Release Tablet for Pediatrics (mg/day), January’2020
Figure 6-4: Metformin - Recommended Initial & Maximum Dose of Extended Release Tablet for Pediatrics (mg/day), January’2020
Figure 6-5: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 500mg Glucophage Tablet (US$/SAR), January’2020
Figure 6-6: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of 850mg Glucophage Tablet (US$/ SAR), January’2020
Figure 6-7: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of 1gm Glucophage Tablet (US$/ SAR), January’2020
Figure 6-8: Saudi Arabia - Price for 30, 60 & 90 Tablet Supply & Price per unit of 500mg Glucare XR Tablet (US$/SAR), January’2020
Figure 6-9: Saudi Arabia - Price for 30 & 60 Tablet Supply & Price per unit of 750mg Glucare XR Tablet (US$/SAR), January’2020
Figure 6-10: Saudi Arabia - Price for 60 Tablet Supply & Price per unit of 1000mg Glucare XR Tablet (US$/SAR), January’2020
Figure 6-11: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 500mg Dimetor Tablet (US$/SAR), January’2020
Figure 6-12: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 850mg Dimetor Tablet (US$/SAR), January’2020
Figure 6-13: Saudi Arabia - Price for 30 & 60 Tablet Supply & Price per unit of 750mg Formit XR Tablet (US$/SAR), January’2020
Figure 6-14: Gliclazide - Recommended Initial & Maximum Dose for Adults (mg/day), January’2020
Figure 6-15: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Diamicron MR Tablet (US$/SAR), January’2020
Figure 6-16: Saudi Arabia - Price for 20 Tablet Supply & Price per unit Glaze 80mg Tablet (US$/SAR), January’2020
Figure 6-17 Saudi Arabia - Price for 60 Tablet Supply & Price per unit Glaze 80mg Tablet (US$/SAR), January’2020
Figure 6-18: Saudi Arabia - Price for 30 Tablet Supply & Price per unit Debacron 80mg Tablet (US$/SAR), January’2020
Figure 6-19: Glimepiride - Recommended Initial & Maximum Dose for Adults (mg/day), January’2020
Figure 6-20: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of Amaryl Tablet (US$/SAR), January’2020
Figure 6-21: Saudi Arabia - Price per unit of Various Dose Regimen of Amaryl Tablet (US$/SAR), January’2020
Figure 6-22: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of Glim Tablet (US$/SAR), January’2020
Figure 6-23: Saudi Arabia - Price per unit of Various Dose Regimen of Glim Tablet (US$/SAR), January’2020
Figure 6-24: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of Glorion Tablet (US$/SAR), January’2020
Figure 6-25: Saudi Arabia - Price per unit of Various Dose Regimen of Glorion Tablet (US$/SAR), January’2020
Figure 6-26: Glibenclamide - Recommended Minimum & Maximum Initial Dose for Adults (mg/day), January’2020
Figure 6-27: Glibenclamide - Recommended Minimum & Maximum Maintenance Dose for Adults (mg/day), January’2020
Figure 6-28: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Daonil Tablet (US$/SAR), January’2020
Figure 6-29: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Glibil Tablet (US$/SAR), January’2020
Figure 6-30: Saudi Arabia - Price for 100 Tablet Supply & Price per unit of Apo-Glyburide Tablet (US$/SAR), January’2020
Figure 6-31: Vildagliptin - Recommended Dose in Combinational & Monotherapy for Type-2 Diabetes Treatment (mg/day), January’2020
Figure 6-32: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Galvus 50mg Tablet (US$/SAR), January’2020
Figure 6-33: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Valdatin 50mg Tablet (US$/SAR), January’2020
Figure 6-34: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Jalra 50mg Tablet (US$/SAR), January’2020
Figure 6-35: Onglyza - Patent Issue & Expiration Year
Figure 6-36: Saxagliptin - Recommended Minimum & Maximum Daily Dose (mg/day), January’2020
Figure 6-37: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Onglyza 2.5mg Tablet (US$/SAR), January’2020
Figure 6-38: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Onglyza 5mg Tablet (US$/SAR), January’2020
Figure 6-39: Januvia - Patent Issue & Expiration Year
Figure 6-40: Saudi Arabia - Price for 28 Tablet Supply & Price per unit of Januvia 100mg Tablet (US$/SAR), January’2020
Figure 6-41: Saudi Arabia - Monthly & Annual Treatment Cost of Type-2 Diabetes using Januvia Tablet (US$/SAR), January’2020
Figure 6-42: Invokana - Patent Issue & Expiration Year
Figure 6-43: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Invokana Tablet (US$/SAR), January’2020
Figure 6-44: Invokana - Recommended Minimum & Maximum Dose for Adults (mg/day), January’2020
Figure 6-45: Forxiga - Recommended Minimum & Maximum Dose for Adults (mg/day), January’2020
Figure 6-46: Saudi Arabia - Price for 28 Tablet Supply & Price per unit of Forxiga Tablet (US$/SAR), January’2020
Figure 6-47: Jardiance - Patent Issue & Expiration Year
Figure 6-48: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Jardiance Tablet (US$/SAR), January’2020
Figure 6-49: Jardiance - Recommended Minimum & Maximum Initial Dose for Adults (mg/day), January’2020
Figure 6-50: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Novonorm Tablet (US$/SAR), January’2020
Figure 6-51: Repaglinide - Recommended Minimum & Maximum Initial Dose for Adults (mg/meal), January’2020
Figure 6-52: Pioglitazone - Recommended Minimum & Maximum Initial Dose for Adults (mg/meal), January’2020
Figure 6-53: Saudi Arabia - Price for 30 Tablet Supply of Actos 15mg & 30mg Tablet (US$/SAR), January’2020
Figure 6-54: Saudi Arabia - Price for 30 Tablet Supply of Glacera 15mg, 30mg & 45mg Tablet (US$/SAR), January’2020
Figure 6-55: Saudi Arabia - Price for 30 Tablet Supply of Glados 15mg, 30mg & 45mg Tablet (US$/SAR), January’2020
Figure 6-56: Saudi Arabia - Price for 30 Tablet Supply of Acarose 50mg & 100mg Tablet (US$/SAR), January’2020
Figure 6-57: Saudi Arabia - Price for 30 Tablet Supply of Glucobay 50mg & 100mg Tablet (US$/SAR), January’2020
Figure 6-58: Acarbose - Recommended Initial & Maintenance Dose for Adults (mg/day), January’2020
Figure 6-59: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 250/1.25mg Tablet (US$/SAR), January’2020
Figure 6-60: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 500/2.5mg Tablet (US$/SAR), January’2020
Figure 6-61: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 500/5mg Tablet (US$/SAR), January’2020
Figure 6-62: Saudi Arabia - Price for 30 Tablet Supply of Diamet 250/2.5mg, 500/2.5mg & 500/5mg Tablet (US$/SAR), January’2020
Figure 6-63: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Glucovance 500/2.5mg Tablet (US$/SAR), January’2020
Figure 6-64: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Glucovance 500/5mg Tablet (US$/SAR), January’2020
Figure 6-65: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Amaryl M 2/500mg Tablet (US$/SAR), January’2020
Figure 6-66: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Galvus Met 1000/50mg Tablet (US$/SAR), January’2020
Figure 6-67: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Galvus Met 850/50mg Tablet (US$/SAR), January’2020
Figure 6-68: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Jalra M 1000/50mg Tablet (US$/SAR), January’2020
Figure 6-69: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Jalra M 850/50mg Tablet (US$/SAR), January’2020
Figure 6-70: Saudi Arabia - Price for 56 Tablet Supply of 850/50mg & 1000/50mg Combinational Metformin/Sitagliptin Tablet (US$/SAR), January’2020
Figure 6-71: Kombiglyze XR - Patent Issue & Expiration Year
Figure 6-72: Saudi Arabia - Price for 30 Tablet Supply of 500/5mg, 1000/5mg & 1000/2.5mg Kombiglyze XR Tablet (US$/SAR), January’2020
Figure 6-73: Synjardy XR - Patent Issue & Expiration Year
Figure 6-74: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of 500/5mg, & 500/12.5mg Synjardy XR Tablet (US$/SAR), January’2020
Figure 6-75: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of 1000/5mg, & 1000/12.5mg Synjardy XR Tablet (US$/SAR), January’2020
Figure 6-76: Xigduo XR - Patent Issue & Expiration Year
Figure 6-77: Saudi Arabia - Price for 56 Tablet Supply & Price per Unit of 500/5mg  Xigduo XR Tablet (US$/SAR), January’2020
Figure 6-78: Saudi Arabia - Price for 28 Tablet 500/10mg, 1000/5mg & 1000/10mg Xigduo XR Tablet (US$/SAR), January’2020
Figure 7-1: Lantus - Patent Issue & Expiration Year
Figure 7-2: Saudi Arabia - Price for 10ml Vial & Price per ml of Lantus (US$/SAR), January’2020
Figure 7-3: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Lantus (US$/SAR), January’2020
Figure 7-4: Saudi Arabia - Price for 10ml Vial & Price per ml of Humulin 70/30 (US$/SAR), January’2020
Figure 7-5: Saudi Arabia - Price for 10ml Vial & Price per ml of Humulin N-NPH (US$/SAR), January’2020
Figure 7-6: Saudi Arabia - Price for 10ml Vial & Price per ml of Humalog (US$/SAR), January’2020
Figure 7-7: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Humalog (US$/SAR), January’2020
Figure 7-8: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Humalog Mix 25 & 50 (US$/SAR), January’2020
Figure 7-9: Saudi Arabia - Price for 10ml Vial & Price per ml of Mixtard 30 (US$/SAR), January’2020
Figure 7-10: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Mixtard 40 Novolet (US$/SAR), January’2020
Figure 7-11: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Mixtard 50 HM Novolet (US$/SAR), January’2020
Figure 7-12: Apidra - Patent Issue & Expiration Year
Figure 7-13: Saudi Arabia - Price for a 5 Vial Supply & Price per Vial of Apidra (US$/SAR), January’2020
Figure 7-14: Saudi Arabia - Price for 10ml Vial & Price per ml of Insulatard (US$/SAR), January’2020
Figure 8-1: Saudi Arabia - Diabetes Device Market Opportunity (US$ Million), 2019-2025
Figure 8-2: Saudi Arabia - Number of Insulin Users (Million), 2019-2025
Figure 9-1: Saudi Arabia - Price for Supply of 90 & Price per unit of 8 mm BD Ultra-fine Insulin Syringe 31G, 1/2cc (US$/SAR), January’2020
Figure 9-2: Saudi Arabia - Price for Supply of 100 & Price per unit of 8 mm BD Ultra-fine Insulin Syringe 31G, 3/10cc (US$/SAR), January’2020
Figure 9-3: Saudi Arabia - Price for Supply of 90 & Price per unit of 6 mm BD Ultra-fine Insulin Syringe 31G, 3/10cc (US$/SAR), January’2020
Figure 9-4: Saudi Arabia - Price for Supply of 90 & Price per unit of 0.5 inch BD Ultra-fine Insulin Syringe 30G, 3/10cc (US$/SAR), January’2020
Figure 9-5: Saudi Arabia - Price for Supply of 100 Care Touch 28G, 29G, 30G & 31G Insulin Syringe (US$/SAR), January’2020
Figure 9-6: Saudi Arabia - Insulin Syringe Consumption by 20% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-7: Saudi Arabia - Insulin Syringe Consumption by 30% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-8: Saudi Arabia - Insulin Syringe Consumption by 40% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-9: Saudi Arabia - Insulin Syringe Consumption by 50% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-10: Saudi Arabia - Insulin Pen Market Opportunity (US$ Million), 2019-2025
Figure 9-11: Commercially Available Insulin Pens
Figure 9-12: Saudi Arabia - Insulin Pen Consumption by 20% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-13: Saudi Arabia - Insulin Pen Consumption by 30% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-14: Saudi Arabia - Insulin Pen Consumption by 40% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-15: Saudi Arabia - Insulin Pen Consumption by 50% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-16: Saudi Arabia - Insulin Pen Consumption by 60% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-17: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lispro Containing Humalog Kwikpen (US$/SAR), January’2020
Figure 9-18: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lispro & Protamine Containing Humalog Kwikpen (US$/SAR), January’2020
Figure 9-19: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Novomix Flexpen (US$/SAR), January’2020
Figure 9-20: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Novorapid Flexpen (US$/SAR), January’2020
Figure 9-21: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lemevir Flexpen (US$/SAR), January’2020
Figure 9-22: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lantus Solostar (US$/SAR), January’2020
Figure 9-23: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar (US$/SAR), January’2020
Figure 9-24: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar 100,33mcg/ml (US$/SAR), January’2020
Figure 9-25: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar 100,50mcg/ml (US$/SAR), January’2020
Figure 9-26: Saudi Arabia - Price of Novopen 3, 4, 5 & Novopen Echo (US$/SAR), January’2020
Figure 9-27: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 100units/ml Tresiba Flextouch pen (US$/SAR), January’2020
Figure 9-28: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January’2020
Figure 9-29: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January’2020
Figure 9-30: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January’2020
Figure 9-31: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January’2020
Figure 9-32: Types of Insulin Pumps
Figure 9-33: Saudi Arabia - Insulin Pump Consumption by 5% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-34: Saudi Arabia - Insulin Pump Consumption by 10% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-35: Saudi Arabia - Insulin Pump Consumption by 15% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-36: Saudi Arabia - Insulin Pump Consumption by 20% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-37: Saudi Arabia – Insulin Jet Injectors Consumption by 5% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-38: Saudi Arabia – Insulin Jet Injectors Consumption by 10% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-39: Saudi Arabia - Insulin Jet Injectors Consumption by 15% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-40: Saudi Arabia - Insulin Jet Injectors Consumption by 20% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 9-41: Saudi Arabia - Insulin Jet Injectors Consumption by 25% of Total Insulin Delivery Device Users (000’), 2019-2025
Figure 10-1: Saudi Arabia - Commercially Available Glucose Monitoring Devices
Figure 10-2: Saudi Arabia - Glucose Monitoring Device Market Opportunity (US$ Million), 2019-2025
Figure 10-3: Saudi Arabia - Price for Various Accu-Chek Blood glucose Monitoring Device (US$/SAR), January’2020
Figure 10-4: Saudi Arabia - Price for Various Supplies of Accu-Chek Performa Test Strips (US$/SAR), January’2020
Figure 10-5: Saudi Arabia - Price for 50 Strips & Price for Single Test Strip of Accu-Chek Active (US$/SAR), January’2020
Figure 10-6: Saudi Arabia - Price for 50 Strips & Price for Single Test Strip of Accu-Chek Instant (US$/SAR), January’2020
Figure 10-7: Saudi Arabia - Price for Supply of 50 & Price for Single Lancet of Accu-Chek Softclinx (US$/SAR), January’2020
Figure 10-8: Saudi Arabia - Price for Supply of 102 & 204 Lancets of Accu-Chek Fastclinx (US$/SAR), January’2020
Figure 10-9: Saudi Arabia - Price for Abbott’s Freestyle Optimum Glucometer, Test Strip & Lancets (US$/SAR), January’2020
Figure 10-10: Saudi Arabia - Price for Bayes Contour & Easy Max Glucometer (US$/SAR), January’2020
Figure 10-11: Saudi Arabia - Price for 50 Lancet Supply and Price per unit of Bayes Contour Test Strips (US$/SAR), January’2020
Figure 10-12: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 40% of Diagnosed Diabetics (Million), 2019-2025
Figure 10-13: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 50% of Diagnosed Diabetics (Million), 2019-2025
Figure 10-14: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 60% of Diagnosed Diabetics (Million), 2019-2025
Figure 10-15: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 70% of Diagnosed Diabetics (Million), 2019-2025
Figure 10-16: Saudi Arabia – Self-Regulating Blood Glucose Monitor Consumption by 80% of Diagnosed Diabetics (Million), 2019-2025
Figure 10-17: Saudi Arabia - Price of Freestyle Libre Sensor & Receiver (US$/SAR), January’2020
Figure 10-18: Saudi Arabia - Price of Dexcom G5 Sensor, Receiver & Transmitter (US$/SAR), January’2020
Figure 10-19: Saudi Arabia - Price of Dexcom G6 Sensor, Receiver & Transmitter (US$/SAR), January’2020
Figure 10-20: Saudi Arabia - Price of a Supply of 3 Sensor & Price for Single Sensor of Dexcom G6 (US$/SAR), January’2020
Figure 10-21: Saudi Arabia - Price for a Supply of 5 Sensor & Price for Single Sensor of Guardian Sensor 3 (US$/SAR), January’2020
Figure 10-22: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 10% of Diagnosed Diabetics (000’), 2019-2025
Figure 10-23: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 20% of Diagnosed Diabetics (000’), 2019-2025
Figure 10-24: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 30% of Diagnosed Diabetics (000’), 2019-2025
Figure 10-25: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 40% of Diagnosed Diabetics (000’), 2019-2025
Figure 11-1: Saudi Arabia – Total Number of Clinical Trial v/s Diabetes related Trials, 2020
Figure 11-2: Saudi Arabia – Number of Diabetes related Clinical Trials by Development Phase, 2020
Figure 11-3: Saudi Arabia – Number of Diabetes related Clinical Trials by Development Phase, 2020
Figure 11-4: Saudi Arabia – Number of Clinical Trials by Status, 2019
Figure 13-1: Saudi Arabian Diabetes Market Drivers
Figure 13-2: Challenges for Saudi Arabia Diabetes Market
Note: Product cover images may vary from those shown

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • Abbott
  • Aljazeera Pharmaceutical Industries
  • Al Mojil Drug Company
  • AstraZeneca
  • Bayer
  • CAD Middle-East Pharmaceutical Company
  • Eli - Lilly
  • Julphur Pharmaceuticals
  • Kuwait Saudi Pharmaceutical Company
  • Merck
  • Novartis
  • Oman Pharmaceuticals
  • Roche
  • Saja Pharmaceuticals
  • Sanofi
  • Servier
  • SPIMACO Addwaeih
  • Tabuk Pharmaceuticals
  • Qatar Life Pharma
  • YIACO Medical Company
Note: Product cover images may vary from those shown